Skip to main content

Table 1 Resistant cell lines

From: DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer

Parental cell lineRRIDOriginTherapy drugParental IC50Therapy targetExposure periodResistant cell lineResistant IC50EMTRef
HepG2 (n = 2)CVCL_0027LiverSorafenib0.28 μMVEGFR, PDGFR, Raf kinases6–12 monthsHepG2S10.44 μMFull[16]
HepG2S30.69 μMFull
HCC4006P1CVCL_1269LungErlotinib0.03 μMEGFR3–6 monthsHCC4006ER0.97 μMFull[17]
Panc 03.27 (‘PancVB’) (n = 2)CVCL_1635Pancreas5-Fluorouracil14.63 μMThymidylate synthase6 monthsPancB1Q55.72 μMFull[18]
PancB1V30.75 μMFull
HCC4006P2CVCL_1269LungGefitinib0.10 μMEGFR3 monthsHCC4006GR0.59 μMFull[19]
HCC827PCVCL_2063LungGefitinib0.027 μMEGFR3 monthsHCC827GR0.046 μMFull
UWB 1.289 (n = 2)CVCL_B079OvaryOlaparib58.02 μMPARP5 monthsU10512.33 μMPartial[20]
U100699.41 μMPartial
IGROV-1CVCL_1304OvaryCisplatin64.04 μMDNA replication9 monthsIGROV-1/CDDP388.02 μMPartial[21]
  1. The columns indicate which established cell line was used as the parental cell line, their Research Resource Identifiers (RRID), their tissue of origin, the drug they were made resistant to, the concentration of the drugs at which their growth was inhibited by 50% (IC50), the target of the drug, the period over which they were rendered resistant, the name of their resistant counterparts, the concentration of drugs at which the growth of the resistant cells was inhibited by 50% (IC50), their EMT status and the reference of the paper describing their retrieval